Novo Nordisk Shares Jump After Successful Completion of First Phase IIIa Trial For its GLP-1 Analogue Semaglutide

Shares of Novo Nordisk A/S (ADR) [NYSE:NVO] jumped 5.31% to close at $57.68 a share on Friday, after the ...

Vertex Pharmaceuticals Shares Jumped after FDA Approves Their Cystic Fibrosis Drug Orkambi (lumacaftor/ivacaftor)

Shares of Vertex Pharmaceuticals, Inc. [NASDAQ: VRTX] jumped 4.60% to an intraday high of $132 a share on ...

Juno Therapeutics Shares Jumped After Announcing Collaboration of its CAR T and T Cell Receptor Technologies with Celgene

Shares of Juno Therapeutics, Inc. [NASDAQ:JUNO] jumped 36.07% to an intra-day high of $63.00 per share on ...

Juno Therapeutics Shares Tumble as Insiders Sell After the IPO Lock-Up Period Expires

Shares of Juno Therapeutics, Inc. [NASDAQ:JUNO] tumbled 12.14% to close at $51.33 per share on Wednesday, after the expiration of lock-up period restrictions. The lock-up period ...

Avalanche Biotech Shares Tumbled as its Results From Top-Line Phase 2a AVA-101 Gene Therapy in Wet-AMD Missed Expectations

Shares of Avalanche Biotechnologies, Inc. [NASDAQ:AAVL] tumbled 56.20% to close at $17.03 per share on Tuesday ...

Advisory Panel to FDA Backs Amgen’s Repatha (evolocumab) for Treatment of Heterozygous and Homozygous Familial Hypercholesterolemia

Shares of Amgen, Inc. [NASDAQ:AMGN] surged 1.55% to close at $157.96 per share on Thursday after the ...

Advisory Panel to FDA Gives Nod to Sanofi/Regeneron’s Praluent (alirocumab) for Treatment of Hypercholesterolemia

Shares of Regeneron Pharmaceuticals [NASDAQ:REGN] dropped 2.62% to close at $512.32 per share on ...

Seattle Genetics Surged on Several Encouraging Data of Adcetris (brentuximab vedotin) Presented at the ASCO Annual Meeting

Shares of Seattle Genetics [NASDAQ: SGEN] jumped 7.03% to an intra-day high of $46.44 per share on Tuesday after ...

Gilead Shares Surged on Positive Results from Phase III Clinical Study 119 of Leukemia Drug Zydelig (idelalisib)

Shares of Gilead Sciences, Inc. [NASDAQ: GILD] jumped 1.61% on Monday after the company said that their Phase ...

Actavis Shares Surged After Viberzi Gets FDA Approval for Irritable Bowel Syndrome

Shares of Actavis Plc [NYSE:ACT] and Valeant Pharmaceuticals International Inc. [NYSE:VRX] surged 2.05% and 1.09%, respectively, on Thursday after the U.S. Food ...

Seattle Genetics Posts Narrower-than-Expected Loss in Q1 on Adcetris Sales and ADC Collaboration Milestone Payments

Seattle Genetics Inc. [NASDAQ: SGEN] said its revenues for the first quarter 2015 were $82.2 million, compared to ...

Regeneron Shares Break Out on Positive Pivotal Phase 2b Dupilumab Data in Asthma

Shares of Regeneron Pharmaceuticals [NASDAQ:REGN] surged 2.32% to an intra-day high of $500.36 per share on Monday, May 18, after the company reported positive ...

Actavis Beats Big on First-Quarter 2015 Earnings and Revenues

In the first-quarter ended March 2015, Actavis Plc [NYSE:ACT] reported revenues of $4.23 billion, up 59% year-over-year and non-GAAP EPS with ex-items of $4.30 ...

Nasdaq Biotechnology Index Surges as the ASCO Annual Meeting is Less Than Two Weeks Away

The iShares Nasdaq Biotechnology ETF [NASDAQ:IBB], which tracks the Nasdaq Biotechnology Index [NASDAQ:NBI], has surged 7.68% since the beginning of May in anti ...

Jazz Pharmaceuticals Beats First-Quarter Revenues Driven by Strong Sales of Narcolepsy Drug Xyrem

In the first-quarter ended March 2015, Jazz Pharmaceuticals [NASDAQ:JAZZ] reported revenues of $309.3 million ...

Regeneron’s First-Quarter Earnings Beat as its Eylea (aflibercept) Eye Drug Global Sales Jumped 44%

In the first-quarter ended March 2015, Regeneron Pharmaceuticals [NASDAQ:REGN] reported total revenues ...

Novo Nordisk Beats on First-Quarter Earnings as Victoza and Levemir Continue to Drive Sales Growth

In the first-quarter ended March 2015, Novo Nordisk A/S (ADR) [NYSE:NVO] reported net sales of Danish kroner ...

Celgene Beats on Earnings But Revenue From Multiple Myeloma Drug, Revlimid, Dented by a Strong Dollar

In the first-quarter ended March 2015, Celgene Corp. [NASDAQ:CELG] reported total revenues of $2.08 billion ...

Biogen Missed First-Quarter Earnings and Revenues as Tecfidera Sales Growth Moderated

In the first-quarter ended March 2015, Biogen [NASDAQ:BIIB] reported total revenues of $2.55 billion, up 20% year-over-year and non-GAAP diluted earnings per share (EPS) of $3.89 ...

Jazz Pharmaceuticals Ran Up Almost 7% Today as the Neverending M&A Rumors Resurface

UK-based Mylan NV [NASDAQ:MYL], a global company for branded generic and specialty pharmaceuticals, said today that the company has offered to acquire Dublin, Ireland- ...